Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEACRAFT-2: naporafenib + trametinib versus physician's choice in previously treated NRAS-mutant unresectable or metastatic cutaneous melanoma
2024-511404-17-00Phase 3Authorised
- Sponsor
- Erasca
- Start
- Sep 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of naporafenib, trametinib, dacarbazine and temozolomide in cutaneous melanoma (CM) (2 arms), sponsored by Erasca. Primary endpoints: Dose optimization assessment, Progression-free survival and 1 more. Planned start Sep 2024; status: authorised.
02
Drugs
naporafenibtrametinibdacarbazinetemozolomide
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2024-511404-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511404-17-00.